UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024
UroGen Pharma (Nasdaq: URGN), a biotech company focused on urothelial and specialty cancers, has announced it will release its second quarter 2024 financial results on Tuesday, August 13, 2024, before the stock market opens. The company will host a live audio webcast and conference call at 10:00 AM Eastern Time on the same day to discuss the results. Investors can access the webcast through UroGen's Investor Relations website, where a replay will be available for approximately 30 days after the event. This announcement provides an opportunity for stakeholders to gain insights into UroGen's financial performance and future outlook.
UroGen Pharma (Nasdaq: URGN), una azienda biotecnologica focalizzata sui tumori uroteliali e speciali, ha annunciato che pubblicherà i propri risultati finanziari del secondo trimestre 2024 martedì 13 agosto 2024, prima dell'apertura del mercato azionario. L'azienda ospiterà una webcast audio e una conferenza telefonica in diretta alle 10:00 AM, orario orientale, lo stesso giorno per discutere i risultati. Gli investitori possono accedere alla webcast tramite il sito web delle Relazioni con gli Investitori di UroGen, dove sarà disponibile una registrazione per circa 30 giorni dopo l'evento. Questo annuncio offre un'opportunità per le parti interessate di ottenere informazioni sulle performance finanziarie e le prospettive future di UroGen.
UroGen Pharma (Nasdaq: URGN), una empresa biotecnológica centrada en cánceres uroteliales y especiales, ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 el martes 13 de agosto de 2024, antes de la apertura del mercado de valores. La compañía llevará a cabo una transmisión en vivo de audio y conferencia telefónica a las 10:00 AM, hora del Este, el mismo día para discutir los resultados. Los inversores pueden acceder a la transmisión a través del sitio web de Relaciones con Inversores de UroGen, donde estará disponible una repetición durante aproximadamente 30 días después del evento. Este anuncio brinda una oportunidad a los interesados para obtener información sobre el desempeño financiero y las perspectivas futuras de UroGen.
UroGen Pharma (Nasdaq: URGN)는 요로상피 및 특수 암에 집중하는 생명공학 회사로, 2024년 2분기 재무 결과를 2024년 8월 13일 화요일 주식 시장 개장 전 발표할 것이라고 발표했습니다. 회사는 같은 날 오전 10시 동부 시간에 실시간 오디오 웹캐스트 및 컨퍼런스 콜을 개최하여 결과에 대해 논의할 예정입니다. 투자자들은 UroGen의 투자자 관계 웹사이트를 통해 웹캐스트에 접속할 수 있으며, 이벤트 후 약 30일 동안 재생이 가능할 것입니다. 이 발표는 이해관계자들에게 UroGen의 재무 성과 및 향후 전망에 대한 통찰력을 얻을 수 있는 기회를 제공합니다.
UroGen Pharma (Nasdaq: URGN), une entreprise biopharmaceutique spécialisée dans les cancers urotéliaux et particuliers, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 le mardi 13 août 2024, avant l'ouverture des marchés boursiers. La société tiendra un webinaire audio en direct et une conférence téléphonique à 10h00, heure de l'Est, le même jour pour discuter des résultats. Les investisseurs peuvent accéder au webinaire via le site des Relations Investisseurs d'UroGen, où un replay sera disponible pendant environ 30 jours après l'événement. Cette annonce offre une opportunité aux parties prenantes d'obtenir des informations sur la performance financière et les perspectives futures d'UroGen.
UroGen Pharma (Nasdaq: URGN), ein biotechnologisches Unternehmen, das sich auf uroteliale und spezielle Krebserkrankungen konzentriert, hat angekündigt, dass es am Dienstag, den 13. August 2024, vor der Eröffnung des Aktienmarktes seine Finanzergebnisse für das zweite Quartal 2024 veröffentlichen wird. Das Unternehmen wird am selben Tag um 10:00 Uhr Eastern Time eine Live-Audio-Webcast- und Telefonkonferenz veranstalten, um die Ergebnisse zu besprechen. Anleger können über die Investor-Relations-Website von UroGen auf die Webcast zugreifen, wo eine Wiederholung etwa 30 Tage nach der Veranstaltung verfügbar sein wird. Diese Ankündigung bietet den Stakeholdern die Möglichkeit, Einblicke in UroGens finanzielle Leistung und zukünftige Perspektiven zu gewinnen.
- None.
- None.
Conference Call and Webcast Scheduled for Tuesday, August 13, 2024, at 10:00 AM ET
A live public webcast of the earnings conference call can be accessed on UroGen’s Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat low-grade upper tract urothelial cancer and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer are designed to ablate tumors by non-surgical means. UroGen is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240805414962/en/
INVESTOR CONTACT:
Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093
MEDIA CONTACT:
Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3583 ext. 1083
Source: UroGen Pharma Ltd.
FAQ
When will UroGen Pharma (URGN) report its Q2 2024 financial results?
What time is UroGen Pharma's (URGN) Q2 2024 earnings conference call?
How can investors access UroGen Pharma's (URGN) Q2 2024 earnings call?
How long will the replay of UroGen Pharma's (URGN) Q2 2024 earnings call be available?
